West Pharmaceutical Services, Inc. · NYSE:WST
West Pharmaceutical Services — Q2 2022 Earnings Presentation
20 slides from West Pharmaceutical Services's earnings presentation, Jul 28, 2022
Slide 1: Second-Quarter 2022 Earnings
1 Second-Quarter 2022 Second Quarter Overall Net Sales $771.3M | 6.6% Diluted Earnings Per Share: $2.48 Adjusted Diluted Earnings Per Share: $2.47 Eric M. Green President and Chief Executive Officer, Chair of the Board West Pharmaceutical Services, Inc. WST Q2 2022 Earnings Cautionary Statement Unde
Slide 2: Second-Quarter Results 2022 Analyst Conference Call
West Pharmaceutical Services, Inc. Eric M. Green President & CEO, Chair of the Board Bernard J. Birkett Senior VP & Chief Financial and Operations Officer Second-Quarter Results 2022 Analyst Conference Call 9 a.m. Eastern Time | July 28, 2022
Slide 3: West Analyst Conference Call
3 West Analyst Conference Call 9 a.m. Eastern Time July 28, 2022 A webcast of today’s call can be accessed in the “Investors” section of the Company’s website: www.westpharma.com To participate on the call by asking questions to Management, please register in advance at https://bit.ly/3z4iU0g. Upon
Slide 4: Safe Harbor Statement
4 Safe Harbor Statement This presentation and any accompanying management commentary contain “forward- looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about product development and operat
Slide 5: Financial Highlights
5 Financial Highlights WST Q2 2022 Earnings • Second quarter 2022 net sales of $771.3 million grew 6.6%; organic net sales growth was 13.1% • Second quarter 2022 reported-diluted EPS of $2.48 compared to $2.47 in the same period last year; adjusted-diluted EPS of $2.47 compared to $2.46 in the same
Slide 6: Advancing the Standard of Care for Patients
6 Nova P u r e ® Co m p o nen ts S m a r t D o s e ® O n -B o dy D el ivery System Da i kyo ® Crystal Z en i th ® 1 & 2. 25 m L In s er t Ne e d l e System Advancing the Standard of Care for Patients Execute. Innovate. Grow. WST Q2 2022 Earnings
Slide 7: Purpose. Driven.
7 Purpose. Driven. 250+ charitable organizations that West partnered with across the globe in water intensity 64% of West’s C-suite comprised of women, people of color or international diversity in energy intensityin waste recycled and global waste diversion at sites 2021 Corporate Responsibility Re
Slide 8: Second-Quarter 2022 Summary Results
8 Second-Quarter 2022 Summary Results ($ millions, except earnings-per-share (EPS) data) Three Months Ended June 30 2022 2021 Reported Net Sales $771.3 $723.6 Gross Profit Margin 41.7% 43.5% Reported Operating Profit $228.4 $211.3 Adjusted Operating Profit (1) $227.0 $211.2 Reported Operating Profit
Slide 9: Second-Quarter 2022 Organic Net Sales Growth
9 Overall Organic Net Sales Growth – 13.1% (Q2 2022) Proprietary Products Q2 2022 organic net sales growth of 18.3% led by sales of high-value products, which grew double digits BIOLOGICS GENERICS PHARMA Sales led by high-value products, including NovaPure® components Sales led by high-value product
Slide 10: Change in Consolidated Net Sales
10 Change in Consolidated Net Sales Second-quarter 2021 to 2022 ($ millions) WST Q2 2022 Earnings
Slide 11: Gross Profit Update
11 Gross Profit Update ($ millions) Three Months Ended June 30, 2022 2021 Proprietary Products Gross Profit $302.3 $292.3 Proprietary Products Gross Profit Margin 46.2% 49.8% Contract-Manufactured Products Gross Profit $19.2 $22.8 Contract-Manufactured Products Gross Profit Margin 16.3% 16.7% Consol
Slide 12: Cash Flow and Balance Sheet Metrics
12 Cash Flow and Balance Sheet Metrics ($ millions) Cash Flow Items YTD Q2 2022 YTD Q2 2021 Depreciation and Amortization $59.7 $57.9 Operating Cash Flow $324.3 $233.1 Capital Expenditures $131.9 $111.6 Free Cash Flow $192.4 $121.5 Financial Condition June 30, 2022 December 31, 2021 Cash and Cash Eq
Slide 13: 2022 Full-Year Guidance
13 2022 Full-Year Guidance 2022 Full-Year Guidance Consolidated Net Sales $2.950 - $2.975 billion Adjusted-Diluted EPS $9.00 - $9.15 WST Q2 2022 Earnings
Slide 14: Driven by our collective purpose to improve patient lives
14 We are driven by our collective purpose to improve patient lives. WST Q2 2022 Earnings Execute. Innovate. Grow. Delivering Unique Value to Customers & Patients Global Operational Effectiveness Across the Network Accelerating Investments for the Future
Slide 15: Q & A
15 Eric M. Green President and Chief Executive Officer, Chair of the Board Bernard J. Birkett Senior VP and Chief Financial and Operations Officer Quintin Lai VP, Corporate Strategy & Investor Relations Q & A WST Q2 2022 Earnings
Slide 16: Notes to Non-U.S. GAAP Financial Measures
16 Notes to Non-U.S. GAAP Financial Measures The Non-U.S. GAAP financial measures are incorporated into our discussion and analysis as management uses them in evaluating our results of operations and believes that this information provides users a valuable insight into our overall performance and fi
Slide 17: Notes to Non-U.S. GAAP Financial Measures
17 Notes to Non-U.S. GAAP Financial Measures RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED) See “Notes to Non-U.S. GAAP Financial Measures”, “Safe Harbor Statement” (Slide 4) and today’s press release for an explanation and reconciliation of these items. Reconciliation of Reported an
Slide 18: Notes to Non-U.S. GAAP Financial Measures
18 Notes to Non-U.S. GAAP Financial Measures RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED) See “Notes to Non-U.S. GAAP Financial Measures”, “Safe Harbor Statement” (Slide 4) and today’s press release for an explanation and reconciliation of these items. Reconciliation of Reported an
Slide 19: Notes to Non-U.S. GAAP Financial Measures
19 Notes to Non-U.S. GAAP Financial Measures RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED) See “Notes to Non-U.S. GAAP Financial Measures”, “Safe Harbor Statement” (Slide 4) and today’s press release for an explanation and reconciliation of these items. Reconciliation of Net Sales t
Slide 20: Notes to Non-U.S. GAAP Financial Measures
20 Notes to Non-U.S. GAAP Financial Measures RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED) See “Notes to Non-U.S. GAAP Financial Measures”, “Safe Harbor Statement” (Slide 4) and today’s press release for an explanation and reconciliation of these items. Reconciliation of Reported-Di
West Pharmaceutical Services — Q2 2022 Earnings Presentation on 6ix